Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study

Abstract

Background In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence. Due to a lack of clinical evidence and expertise, managing these AEs can be challenging for patients and physicians alike. In the absence of evidence, consensus recommendations from physicians experienced in using pirfenidone to treat IPF are beneficial. Methods Using a modified Delphi process, expert recommendations were developed by a panel of physicians experienced with using pirfenidone for IPF. Over three iterations, panelists developed and refined a series of statements on the use of pirfenidone in IPF. Their agreement on each statement was ranked using a Likert scale. Results A panel of 12 physicians participated and developed a total of 286 statements on dosing and administration, special populations, drug-drug interactions, laboratory analysis, warnings and precautions, and AE management. Expert recommendations were achieved with regard to slower initial titrations and slower titrations for AEs, dosing with meal(s) or substantial meals, and adding other prescribed pharmacological agents for AEs. Conclusion Until there is further clinical evidence, the resulting consensus recommendations are intended to provide direction on the practical management of IPF with pirfenidone, by encompassing a broad experience from the real world to complement data gleaned from clinical trials.

I-PreFer Study: A Questionnaire to Explore Patient, Caregiver and Pulmonologist Preferences of Idiopathic Pulmonary Fibrosis Treatment Options

“…To facilitate this, the summary of product characteristics (SmPCs) for pirfenidone and nintedanib were compared, to differentiate between the key characteristics of each treatment. 15 , 16 In addition, a Delphi consensus study conducted by Rahaghi et al 17 was reviewed. These documents were used to develop specific questions on prescription decisions and pulmonologist experience in treating IPF.…”

Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach

“…In 2021, a multiphase, iterative, modified Delphi mixed-method consensus-building process was conducted. The Delphi method has limitations such as lack of standardized consensus-defining methods, problems associated with anonymity, and potential lack of generalizability beyond the experts included [ 30 ]. It has therefore been adapted in several ways to fit specific research needs.…”

Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease

“…A stepwise management strategy was followed for preventing and alleviating gastrointestinal and skin-related side effects [23,24]. Liver function test was monitored every 2 weeks.…”